trending Market Intelligence /marketintelligence/en/news-insights/trending/CuSOW1xLlvHIM9SVmVeP-A2 content esgSubNav
In This List

BioLife Solutions, TissueGene ink supply deal for osteoarthritis drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


BioLife Solutions, TissueGene ink supply deal for osteoarthritis drug

BioLife Solutions Inc. entered into a 10-year supply agreement with TissueGene Inc. for the manufacture of Invossa, TissueGene's osteoarthritis drug.

BioLife will provide CryoStor, its clinical-grade cell media, for the manufacturing process of the drug.

Invossa is injected into the knee to relieve pain and improve mobility in osteoarthritis patients. Clinical trials in Korea completed in July demonstrated the drug's efficacy and safety profile.

Kolon Life Science Inc., TissueGene's marketing partner, filed for a biologics license application with the South Korean Ministry of Food and Drug Safety. The drug will also undergo clinical trials and regulatory filings in Japan, and is scheduled to begin phase 3 trials in the U.S. in the second quarter of 2017.